Glycoengineering of antibody (Herceptin) through yeast expression and in vitro enzymatic glycosylation

Chiu-Ping Liu,Tsung-I. Tsai,Ting Cheng,Vidya S. Shivatare,Chung-Yi Wu,Chung-Yi Wu,Chi-Huey Wong
DOI: https://doi.org/10.1073/pnas.1718172115
IF: 11.1
2018-01-08
Proceedings of the National Academy of Sciences
Abstract:Significance The carbohydrate components of glycoproteins are known to affect the structure and function of glycoproteins, and thus it is important to develop effective tools to manipulate and optimize the glycan components of glycoproteins with therapeutic significance. This study demonstrates the discovery of endoglycosidases for the remodeling of glycans on Herceptin, a monoclonal antibody used in the treatment of breast cancer, to optimize its effector functions, especially the antibody-dependent cellular cytotoxicity (ADCC). In addition, a method has been developed for the expression of antibodies from yeast to enable the large-scale synthesis of antibodies for further manipulation of the glycan moiety, using endoglycosidases and stable transglycosylation donors to prepare a homogeneous glycoform with optimized effector functions.
multidisciplinary sciences
What problem does this paper attempt to address?